Evidence map›Paper›PMID 35488718›Full record

ArticleMolecular genetics & genomic medicine2022

Imputed expression of schizophrenia-associated genes and cognitive measures in patients with schizophrenia.

Chiara Fabbri, Gian Marco Leggio, Filippo Drago, Alessandro Serretti

Abstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Regulation ofInternational journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Face pareidolia in male schizophrenia.Schizophrenia (Heidelberg, Germany) · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chiara FabbriDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Gian Marco LeggioDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Filippo DragoDepartment of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy.
Alessandro SerrettiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.ORCID 0000-0003-4363-3759

Funding

Replication of Schizophrenia Associations in CATIER01MH074027 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SULLIVAN, PATRICK F · 2006 to 2007
$715k
NIMH NIH HHS R01 MH074027
6 · The paper itself

Abstract

backgroundCognitive dysfunction is a core manifestation of schizophrenia and one of the best predictors of long-term disability. Genes increasing risk for schizophrenia may partly act through the modulation of cognition.

methodsWe imputed the expression of 130 genes recently prioritized for association with schizophrenia, using PsychENCODE variant weights and genotypes of patients with schizophrenia in CATIE. Processing speed, reasoning, verbal memory, working memory, vigilance, and a composite cognitive score were used as phenotypes. We performed linear regression models for each cognitive measure and gene expression score, adjusting for age, years of education, antipsychotic treatment, years since the first antipsychotic treatment and population principal components.

resultsWe included 425 patients and expression scores of 91 genes (others had no heritable expression; Bonferroni corrected alpha = 5.49e-4). No gene expression score was associated with cognitive measures, though ENOX1 expression was very close to the threshold for verbal memory (p = 6e-4) and processing speed (p = 7e-4). Other genes were nominally associated with multiple phenotypes (MAN2A1 and PCGF3).

conclusionA better understanding of the mechanisms mediating cognitive dysfunction in schizophrenia may help in the definition of disease prognosis and in the identification of new treatments, as the treatment of cognitive impairment remains an unmet therapeutic need.

Indexed as

Antipsychotic AgentsCognition DisordersSchizophreniaCognitionHumansNeuropsychological TestsAntipsychotic Agentscognitiongene expressionmemoryprocessing speedschizophrenia

Identifiers

PMID35488718
PMCPMC9184669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.